Huntington's disease (HD) is themost common neurodegenerative disorder for which no effective cure is yet available. Although several agents have been identified to provide benefits so far, the number of therapeutic options remains limited with only symptomatic treatment available. Over the past few years, we have demonstrated that sphingolipid-based approachesmay open the door to newandmore targeted treatments for the disease. In this study, we investigated the therapeutic potential of stimulating sphingosine-1-phosphate (S1P) receptor 5 by the new selective agonist A-971432 (provided by AbbVie) in R6/2mice, a widely used HD animalmodel. Chronic administration of low-dose (0.1mg/kg) A-971432 slowed down the progression of the disease and significantly prolonged lifespan in symptomatic R6/2mice. Such beneficial effects were associated with activation of pro-survival pathways (BDNF, AKT and ERK) and with reduction of mutant huntingtin aggregation. A-971432 also protected blood-brain barrier (BBB) homeostasis in the same mice. Interestingly, when administered early in the disease, before any overt symptoms, A-971432 completely protected HDmice fromthe classic progressivemotor deficit and preserved BBB integrity. Beside representing a promising strategy to take into consideration for the development of alternative therapeutic options for HD, selective stimulation of S1P receptor 5may be also seen as an effective approach to target brain vasculature defects in the disease.

Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease / Di Pardo, Alba; Castaldo, Salvatore; Amico, Enrico; Pepe, Giuseppe; Marracino, Federico; Capocci, Luca; Giovannelli, Alfredo; Madonna, Michele; van Bergeijk, Jeroen; Buttari, Fabio; van der Kam, Elizabeth; Maglione, Vittorio. - In: HUMAN MOLECULAR GENETICS. - ISSN 0964-6906. - 27:14(2018), pp. 2490-2501. [10.1093/hmg/ddy153]

Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease

Di Pardo, Alba
Primo
Writing – Original Draft Preparation
;
Madonna, Michele;Maglione, Vittorio
2018

Abstract

Huntington's disease (HD) is themost common neurodegenerative disorder for which no effective cure is yet available. Although several agents have been identified to provide benefits so far, the number of therapeutic options remains limited with only symptomatic treatment available. Over the past few years, we have demonstrated that sphingolipid-based approachesmay open the door to newandmore targeted treatments for the disease. In this study, we investigated the therapeutic potential of stimulating sphingosine-1-phosphate (S1P) receptor 5 by the new selective agonist A-971432 (provided by AbbVie) in R6/2mice, a widely used HD animalmodel. Chronic administration of low-dose (0.1mg/kg) A-971432 slowed down the progression of the disease and significantly prolonged lifespan in symptomatic R6/2mice. Such beneficial effects were associated with activation of pro-survival pathways (BDNF, AKT and ERK) and with reduction of mutant huntingtin aggregation. A-971432 also protected blood-brain barrier (BBB) homeostasis in the same mice. Interestingly, when administered early in the disease, before any overt symptoms, A-971432 completely protected HDmice fromthe classic progressivemotor deficit and preserved BBB integrity. Beside representing a promising strategy to take into consideration for the development of alternative therapeutic options for HD, selective stimulation of S1P receptor 5may be also seen as an effective approach to target brain vasculature defects in the disease.
2018
molecular biology; genetics; Huntington's disease
01 Pubblicazione su rivista::01a Articolo in rivista
Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease / Di Pardo, Alba; Castaldo, Salvatore; Amico, Enrico; Pepe, Giuseppe; Marracino, Federico; Capocci, Luca; Giovannelli, Alfredo; Madonna, Michele; van Bergeijk, Jeroen; Buttari, Fabio; van der Kam, Elizabeth; Maglione, Vittorio. - In: HUMAN MOLECULAR GENETICS. - ISSN 0964-6906. - 27:14(2018), pp. 2490-2501. [10.1093/hmg/ddy153]
File allegati a questo prodotto
File Dimensione Formato  
DiPardo_Stimulation_2018.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.5 MB
Formato Adobe PDF
1.5 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1208189
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 33
social impact